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INTRODUCTION
Diabetic kidney disease research: Where do we stand at the
turn of the century?
Diabetes is the leading cause of end-stage renal disease of GFAT increases transforming growth factor (TGF)-b1
in many countries and diabetic nephropathy has emerged synthesis (Schleicher and Weigert). Reactive oxygen spe-
as a silent epidemic worldwide. This is certainly the case cies (ROS) are now proposed as signaling molecules in
in Korea, where diabetic kidney disease accounted for high glucose–induced mesangial cell activation leading to
39% of all new dialysis patients in 1998. Likewise, in the stimulation of PKC and the transcription factors nuclear
United States, diabetic nephropathy accounted for 42% factor-kappa B (NF-kB) and AP-1, and subsequent up-
of all new cases of end-stage renal disease in 1997. The regulation of TGF-b1 and fibronectin expression (Ha
physical and monetary costs of the disease to both the and Lee). In addition, it is hypothesized that ROS may
patient and society are enormous. be the unifying mechanism for diabetic complications
A large body of information has accumulated and im- (Nishikawa, Edelstein, and Brownlee). They have re-
portant progress has been made in the last decade in cently advanced the intriguing postulate that mutations
our understanding of mechanisms involved in the devel- in mitochondrial DNA by high glucose–induced ROS
opment and progression of diabetic complications in- could cause defective electron transport-chain subunits
cluding nephropathy. It is true, however, that effective and increase ROS production even at physiologic con-
treatment of diabetes and prevention of diabetic ne- centrations of glucose to perpetuate tissue injury. This
phropathy remain elusive goals. As we enter the new form of “glycemic memory” may explain how diabetic
century and the new millennium, it is appropriate that complications can develop in the presence of euglycemia
we review the state of the art and project the future that follows a certain period of hyperglycemia.
direction of research in diabetes-related kidney disease. Advanced glycation end products (AGE) appear to
The Fourth Hyonam Kidney Laboratory International be independent risk factors for diabetic nephropathy.
Symposium, entitled “Diabetic kidney disease research: Galectin-3 (Gal-3) is a multifunctional AGE-binding pro-
Where do we stand at the turn of the century?” was tein that associates with other AGE-binding receptor
held in Seoul, Korea, on February 11–13, 2000, under the components rather than serve as an independent AGE-
auspices of the International Society of Nephrology. This receptor. Up-regulation of Gal-3 in the diabetic milieu
symposium provided a forum for experts in diabetes appears to contribute to development of diabetic neph-
research to meet and discuss the roles of glucose metabo- ropathy either by modifying the function of other AGE-
lism, glucose-modified proteins, and relevant growth fac- receptor components or by direct effects on tissue remod-
tors and signal transduction pathways in diabetic renal eling (Pugliese and colleagues). In addition to AGE,
injury. glucose-adducts in the Amadori configuration may play
Overactivity of the aldose reductase pathway in diabe- a pathogenic role in diabetic renal disease in that they
tes may be injurious to the kidney, for example, through are the predominant stable forms of plasma-glycated
activation of protein kinase C (PKC) but long-term inhi- proteins and are significantly increased in the circulation
bition of the enzyme does not effectively prevent those of patients with diabetes (Chen, Cohen, and Ziyadeh).
chronic lesions associated with diabetic nephropathy. One Similar to the effects of high ambient glucose and AGE
plausible explanation for this discrepancy is the ability of levels, Amadori-modified serum albumin induces activa-
aldose reductase to detoxify dicarbonyl compounds and tion of PKC (including the PKC-b isoform), up-regulates
thus alleviate hyperglycemia-induced cellular impairment the TGF-b system, and promotes production of extracel-
(Dunlop). The hexosamine biosynthetic pathway is caus- lular matrix (ECM) proteins in cultured mesangial cells.
ally involved in the development of diabetic nephropathy In fact, the same authors have shown that reduction
through activation of PKC. Glutamine: fructose-6-phos- alone or with neutralization of glycated albumin in the
phate-amidotransferase (GFAT), a rate-limiting step in
db/db mouse model of type 2 diabetes significantly ame-
this pathway, is significantly induced in glomeruli of pa-
liorates proteinuria, renal insufficiency, mesangial expan-tients with diabetic nephropathy and this overexpression
sion, and overexpression of matrix proteins.
Cellular signaling pathways involved in TGF-b–induced
Received for publication April 21, 2000 renal injury are being extensively investigated. The Smad
family of proteins have received the greatest amount ofÓ 2000 by the International Society of Nephrology
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attention as intracellular mediators of TGF-b action, but A (HMG-CoA) reductase inhibitor has been shown to
suppress glomerular TGF-b1 expression and amelioratethe protein kinase signaling cascades may cross-talk with
diabetic nephropathy in streptozotocin-induced diabetesthe Smad pathway and also participate in TGF-b signal-
in rats. Lovastatin-induced down-regulation of TGF-b1ing. Interplay among the different Smad proteins can
and fibronectin in mesangial cell cultures appears to re-modulate TGF-b signaling. Smad 7, an inhibitor of au-
sult from depletion of isoprenoid geranylgeranyl pyro-toinduction of TGF-b, is transcriptionally activated by
phosphate and functional Rho-family small GTP-bindingNF-kB subunit p65/RelA, suggesting that precise under-
proteins in plasma membranes, thus leading to interfer-standing of Smad 7 regulation may provide a novel ap-
ence with cell signaling (Kim and associates).proach in the design of inhibitors of TGF-b signaling
Angiotensin (Ang) II is an important mediator that(Bo¨ttinger and associates). Conversely, the extracellular
cooperates with high ambient glucose levels to inducesignal-regulated kinase (ERK) pathway is required for
renal injury. Increased expression of the angiotensinogenthe peculiar antiapoptotic effects of TGF-b in macro-
gene was demonstrated in mesangial cells cultured underphages and the p38 mitogen-activated protein kinase
high glucose conditions, and high glucose-induced TGF-b1(MAPK) system is involved in TGF-b–induced type I
secretion can be prevented by an Ang II receptor blockercollagen synthesis in mesangial cells (Choi). The ERK
(Leehey and associates).pathway is also involved in TGF-b–induced fibronectin
Vascular endothelial growth factor (VEGF) plays aand plasminogen activator inhibitor (PAI)-1 expression
key role in diabetic retinopathy but little is known aboutin mesangial cells, perhaps independent of the Smad path-
its role in other complications, such as nephropathy. VEGFway (Kikkawa and associates). TGF-b–induced down-regu-
expression is increased in mesangial cells cultured in highlation of inositol 1,4,5-trisphosphate (IP3) receptors may
glucose media, and glomerular VEGF levels and urinarymediate vascular dysfunction in diabetes (McGowan and
VEGF are increased in patients with diabetes (Cha andSharma). IP3 receptor down-regulation has been demon- associates). The role of VEGF in diabetic retinopathy isstrated in the kidney and aorta of streptozotocin-induced
reviewed and preliminary data are reported on ongoingdiabetes in rats and mice, and the effects of TGF-b in
large clinical trials with an agent that blocks the biochem-
the impairment of agonist-induced calcium mobilization ical pathways initiated by VEGF (Aiello and Wong).
in cultured mesangial cells and preglomerular vascular It is hoped that this symposium will stimulate scientists
smooth muscle cells is associated with decreased IP3 re- around the world to continue to search for the factors
ceptor expression. and the mechanisms by which the kidneys are injured in
The cell cycle is altered in the diabetic kidney and this diabetes and to enable us to eventually prevent or reverse
phenomenon may provide for possible therapeutic targets diabetic renal damage in this new century. Dr. Elliot P.
(Wolf). This is based on the observations that angiotensin- Joslin, one of the first clinicians to specialize in the treat-
converting enzyme inhibitors (ACEI) suppress glomeru- ment of diabetes mellitus, wrote in 1931, “With the ad-
lar levels of cyclin-dependent kinase (CDK) inhibitors vent of insulin, we moved from the era of diabetic coma
and prevent glomerular hypertrophy and that p21Cip1- to the era of diabetic complications.” Unfortunately,
knockout mice do not develop glomerular hypertrophy these prophetic words remain as true today as they were
and proteinuria. throughout the last century, despite the great strides
The ECM can have an active role in cell growth, differ- that were made in antihypertensive therapy and glycemic
entiation, and apoptosis. That mesangial cell apoptosis management.
We are grateful to Thomas E. Andreoli, M.D., Presi-is increased when matrix-derived signals to the cells are
dent of the International Society of Nephrology, for sup-inhibited by antisense oligonucleotides to b1-integrin
porting this symposium, and to Saulo Klahr, M.D., Editorsuggests that mesangial cell survival and death are regu-
of Kidney International, for giving us the opportunity tolated by the surrounding ECM (Makino, Sugiyama, and
bring together these contributions in one issue. We alsoKashihara).
thank all the authors and their collaborators who contrib-Down-regulation of ECM degradation, through a TGF-
uted to these proceedings.b–dependent mechanism, may contribute to the patho-
The meeting was generously supported by AstraZen-genesis of diabetic glomerulosclerosis. In mesangial cells,
eca, Baxter Korea, Boryung Pharmaceutical Co., Ltd.,the high glucose-induced down-regulation of matrix met-
Choogwae Pharma Corporation, Gambro Korea, Han-alloproteinases (MMPs) is likely caused by TGF-b–
wha Group, Lilly Korea Ltd., and MSD Korea Ltd.dependent inhibition of MMP promoter activity (McLen-
nan and associates). Hi Bahl Lee, Hunjoo Ha, Sung Il Kim, and Fuad N. Ziyadeh
Guest EditorsLovastatin, the 3-hydroxy-3-methylglutaryl coenzyme
